Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

BACKGROUND: Cyclophosphamide induction regimens for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis are effective in 70 to 90% of patients, but they are associated with high rates of death and adverse events. Treatment with rituximab has led to remission rates of 80 to 90% among pa...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Jones, R, Tervaert, J, Hauser, T, Luqmani, R, Morgan, MD, Peh, C, Savage, C, Segelmark, M, Tesar, V, van Paassen, P, Walsh, D, Walsh, M, Westman, K, Jayne, DR
Fformat:	Journal article
Iaith:	English
Cyhoeddwyd:	2010

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Eitemau Tebyg